| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
CP-96345 targets the NK1 (neurokinin-1) receptor, which is the primary receptor for substance P. It acts as a potent and selective non-peptide NK1 receptor antagonist. By blocking the NK1 receptor, CP-96345 inhibits the effects of substance P, a neuropeptide involved in pain transmission, inflammation, and emesis.
|
|---|---|
| ln Vitro |
In vitro, CP-96345 acts as a highly potent and selective NK1 receptor antagonist. Its activity is typically assessed in receptor binding assays measuring affinity for the NK1 receptor and in functional assays measuring inhibition of substance P-induced signaling. The compound's selectivity for NK1 over other tachykinin receptors (NK2, NK3) can also be evaluated.
|
| ln Vivo |
In vivo, CP-96345 inhibits the decrease in blood pressure caused by substance P and neurokinin A. It attenuates substance P-induced salivary response and inhibits neurogenic inflammation. The compound's oral bioavailability makes it a valuable tool for studying the role of substance P and NK1 receptors in various physiological and pathological processes.
|
| Enzyme Assay |
In cell-free receptor binding assays, CP-96345's activity is evaluated by measuring its affinity for the NK1 receptor. Membrane preparations from cells expressing the NK1 receptor are incubated with a radiolabeled ligand (e.g., [3H]substance P or [125I]Bolton-Hunter substance P) and varying concentrations of CP-96345. The displacement of the radioligand is measured, and the Ki is calculated from the competition curve.
|
| Cell Assay |
In vitro cell-based experiments with CP-96345 typically involve cell lines expressing the NK1 receptor. Cells are treated with the compound in the presence of substance P, and receptor activation is assessed by measuring downstream signaling events such as intracellular calcium mobilization or inositol phosphate accumulation. The inhibition of substance P-induced responses is measured to determine the compound's antagonist potency.
|
| Animal Protocol |
In vivo animal experiments with CP-96345 have been conducted to evaluate its effects on substance P-mediated responses. In typical protocols, rodents are administered the compound orally or intravenously, and substance P-induced salivary secretion is measured. Neurogenic inflammation models (e.g., plasma extravasation) are used to assess the compound's anti-inflammatory effects.
|
| ADME/Pharmacokinetics |
CP-96345 is an orally active compound. Its pharmacokinetic properties include oral bioavailability and distribution to target tissues. The compound has a molecular formula of C28H32N2O and a molecular weight of 412.57. Its half-life and metabolic profile have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for CP-96345. In preclinical studies, the compound has shown efficacy in inhibiting substance P-mediated responses without reported significant toxicity. The compound is for research use only and is not intended for human therapeutic applications.
|
| References | |
| Additional Infomation |
CP-96345 has a molecular formula of C28H32N2O and a molecular weight of 412.57. Its chemical name is (1S,2R,3R,4S)-2-benzhydryl-N-(2-methoxybenzyl)quinuclidin-3-amine. It is a highly potent and selective, orally active NK1 receptor antagonist. CP-96345 attenuates substance P-induced salivary response and inhibits neurogenic inflammation in vivo. It is available for research purposes only.
|
| Molecular Formula |
C28H32N2O
|
|---|---|
| Molecular Weight |
412.57
|
| Exact Mass |
412.251
|
| CAS # |
132746-60-2
|
| PubChem CID |
104943
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.15g/cm3
|
| Boiling Point |
541.5ºC at 760 mmHg
|
| Flash Point |
281.3ºC
|
| Vapour Pressure |
8.65E-12mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
5.408
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
515
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=CC=CC=C1CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
|
| InChi Key |
FLNYLINBEZROPL-NSOVKSMOSA-N
|
| InChi Code |
InChI=1S/C28H32N2O/c1-31-25-15-9-8-14-24(25)20-29-27-23-16-18-30(19-17-23)28(27)26(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-15,23,26-29H,16-20H2,1H3/t27-,28-/m0/s1
|
| Chemical Name |
(2S,3S)-2-benzhydryl-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
|
| Synonyms |
CP96345; CP 96345; CP-96345
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4238 mL | 12.1192 mL | 24.2383 mL | |
| 5 mM | 0.4848 mL | 2.4238 mL | 4.8477 mL | |
| 10 mM | 0.2424 mL | 1.2119 mL | 2.4238 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
